Recurrent Small Cell Lung Cancer: Clinical Trials

7 trials for Recurrent Small Cell Lung Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Completed 7
Phase 22Completed 2

Follow Recurrent Small Cell Lung Cancer: new trials by email Literature Review of Recurrent Small Cell Lung Cancer trials Research Report on Recurrent Small Cell Lung Cancer

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
6,8-bis(benzylthio)octanoic acid - Recurrent Small Cell Lung Cancer
Phase 1CompletedWake Forest University Health Sciences152013-10-012018-07-03
Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
Rovalpituzumab tesirine (SC16LD6.5) - Recurrent Small Cell Lung Cancer
Phase 1 / Phase 2CompletedStemcentrx822013-07-012018-08-09
Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer
questionnaire administration, quality-of-life assessment, counseling intervention - Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Phase 1CompletedWake Forest University Health Sciences62011-01-012018-08-01
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
temsirolimus, vinorelbine ditartrate - Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma
Phase 1CompletedUniversity of Southern California192010-06-012016-06-13
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors
obatoclax mesylate, topotecan hydrochloride, laboratory biomarker analysis - Recurrent Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)222007-08-012015-05-05
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis - Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
Phase 1CompletedNational Cancer Institute (NCI)412001-12-012013-09-30
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
trastuzumab, paclitaxel, recombinant interleukin-12 - Male Breast Cancer, Recurrent Breast Cancer
Phase 1CompletedNational Cancer Institute (NCI)182001-11-012013-06-04

Narrower conditions

Small Cell Lung Carcinoma (7)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Breast Neoplasms (3)  ·  Carcinoma, Ovarian Epithelial (3)  ·  Endometrial Neoplasms (3)  ·  Breast Neoplasms, Male (2)  ·  Prostatic Neoplasms (2)  ·  Stomach Neoplasms (2)  ·  Uterine Cervical Neoplasms (2)  ·  Anus Neoplasms (1)  ·  Appendiceal Neoplasms (1)  ·  Bile Duct Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Islet Cell (1)  ·  Carcinoma, Medullary (1)

Broader conditions

Bronchial Neoplasms (7)  ·  Carcinoma, Bronchogenic (7)  ·  Lung Diseases (7)  ·  Lung Neoplasms (7)  ·  Neoplasms (7)  ·  Neoplasms by Site (7)  ·  Respiratory Tract Diseases (7)  ·  Respiratory Tract Neoplasms (7)  ·  Thoracic Neoplasms (7)  ·  Adnexal Diseases (3)  ·  Breast Diseases (3)  ·  Carcinoma (3)  ·  Digestive System Diseases (3)  ·  Digestive System Neoplasms (3)  ·  Endocrine Gland Neoplasms (3)

Interventions

7-hydroxystaurosporine (1)  ·  Counseling (1)  ·  Early Intervention, Educational (1)  ·  Interleukin-12 (1)  ·  Interleukin-12 Subunit p35 (1)  ·  Irinotecan (1)  ·  Methods (1)  ·  Nicotine Replacement Therapy (1)  ·  Paclitaxel (1)  ·  Sirolimus (1)  ·  Taxes (1)  ·  Topotecan (1)  ·  Trastuzumab (1)  ·  Vinorelbine (1)  ·  devimistat (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  Wake Forest University Health Sciences (2)  ·  Stemcentrx (1)  ·  University of Southern California (1)

Countries

United States (7)

Top investigators

Agustin Garcia (1)  ·  Donald Strickland, MD (1)  ·  Jimmy Ruiz (1)  ·  Kathryn Weaver (1)  ·  Lee Krug (1)  ·  Paula Fracasso (1)  ·  William Carson (1)

Results publications

PMID 21620511, PMID 27932068

NIH funding

P30CA012197 (1), P30CA044579 (1), U01CA076576 (1)